| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10592504 | Bioorganic & Medicinal Chemistry Letters | 2012 | 5 Pages |
Abstract
A series of thienopyridine ureas with dual inhibitory activity against KDR and Aurora B kinase has been identified. Compound 2 (ABT-348) of this series is currently undergoing Phase I clinical trials in solid and hematological cancer populations.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan,